Tipranavir: Difference between revisions

← Older edit

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

David Canner, Alexander Berchansky

@@ Line 1: / Line 1: @@
-<applet   load="" size="480" color="" frame="true"  spin="on" Scene ="Tipranavir/Tipranavir/1" align="right" caption="Tipranavir, better known as Aptivus, ([[2o4p]])"/>
+<StructureSection load='' size='340' side='right' caption='Tipranavir, better known as Aptivus, ([[2o4p]])' scene='Tipranavir/Tipranavir/1'>
 ===Better Known as: Aptivus===
 * Marketed By: Boehringer-Ingelheim<br />
@@ Line 14: / Line 14: @@
 ===Drug Resistance===
 The biggest difficulty with treating [[HIV]] is the rapidity at which it mutates and becomes resistant to treatments. To view a comprehensive and interactive analysis of the mutations which confer drug resistance to [[HIV Protease]], See: [[HIV Protease Inhibitor Resistance Profile]]
+</StructureSection>
 ===Pharmacokinetics===
-{| class="wikitable" border="1" width="52%" style="text-align:center"
+<table style="background: cellspacing="0px"  align="" cellpadding="0px" width="42%">
-|-
+<tr>
-!  colspan="12" align="center"| HIV Protease Inhibitor [[Pharmacokinetics]]<ref>PMID:20400409</ref><ref>Ferry et al, United States Patent US6147095, Pharmacia & Upjohn Company.</ref><ref>L. Veronese et al. Single-Dose Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, in Subjects with Normal or Impaired Hepatic  Function. Antimicrob Agents Chemother. 2000 April; 44(4): 821–826.</ref><ref>J. Ford, et al. Intracellular and Plasma Pharmacokinetics of Saquinavir-Ritonavir, Administered at 1,600/100 Milligrams Once Daily in Human Immunodeficiency Virus-Infected Patients. Antimicrob Agents Chemother. 2004 July; 48(7): 2388–2393.</ref><ref>PMID:10620574</ref><ref>PMID:16086644</ref><ref>PMID:19131522</ref><ref>PMID: 10952482</ref><ref>PMID:16338276</ref><ref>PMID:19729375</ref><ref>PMID:12668574</ref><ref>PMID:17255144</ref><ref>PMID:10858338</ref>
+<td style="width:100%; vertical-align:top;border-width:0px; border-style:inset">
-|-
+<div style="height:100%; width: 100%">
-! Parameter
+{{:HIV Protease Inhibitor Pharmacokinetics}}
-! [[Ritonavir]]
+</div>
-! [[Tipranavir]]
+</td>
-! [[Indinavir]]
+</tr>
-! [[Saquinavir]]
+</table>
-! [[Amprenavir]]
-! [[Fosamprenavir]]
-! [[Lopinavir]]
-! [[Darunavir]]
-! [[Atazanavir]]
-! [[Nelfinavir]]
-|-
-! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr)
-! 4.4
-! ~3
-! 1.5
-! 3.7
-! .98
-! 1.5-4
-! 2
-! .5
-! 2-4
-! 3.1
-|-
-! [[Pharmacokinetics#Cmax|C<sub>max</sub>]] (ng/ml)
-! 13120
-! 14600
-! 8100
-! 2297
-! 4901
-! 4820
-! 11.9
-! 2730
-! ~4393
-! 4701
-|-
-! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%)
-! --
-! --
-! 65
-! 4
-! --
-! --
-! --
-! --
-! 68
-! 20-80
-|-
-! [[Pharmacokinetics#Protein_Binding|Protein Binding]] (%)
-! 99
-! >99
-! 61
-! 98
-! 90
-! 90
-! 99
-! 95
-! 86
-! 98
-|-
-! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
-! 4.8
-! 4.2
-! 1.2
-! 4.5
-! 5.5
-! 7.7
-! 6.1
-! 29.4
-! 5.3
-! 3.3
-|-
-! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
-! 128100
-! 46500
-! 20900
-! 13467
-! 11999
-! 35000
-! 117600
-! 4746
-! ~26045
-! 31906
-|-
-! [[Pharmacokinetics#Clearance_.28Cl.29|Clearance]] (L/h)
-! ~8.4
-! 32.4
-! 49.5
-! 36.7
-! 56.8
-! 84.4
-! 1.7
-! 32.8
-! 13.6
-! 37.3
-|-
-! Dosage (mg)
-! 600
-! 600
-! 800
-! 1000
-! 600
-! 1400
-! 280
-! 400
-! 400
-! 1250
-|-
-! Metabolism
-! Hepatic (CYP3A4 & CYP2C19)
-! Hepatic (CYP3A4)
-! Hepatic (CYP3A4)
-! Hepatic (CYP3A4 & CYP3A5)
-! Hepatic (CYP3A4)
-! Hepatic (CYP3A4)
-! Hepatic (CYP3A4)
-! Hepatic (CYP3A4)
-! Hepatic (CYP3A4)
-! Hepatic (CYP3A4)
-|}
 ===References===